DPP-4 inhibitors × cardiovascular events

TrialThe American journal of medicine2018

Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.

William B White et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 1,398 people · 2018

Randomised comparison

Reduced cardiovascular events

−51%−72% to −16%

Bigger than 9 in 10 for cardiovascular events

As reported

HR 0.49, 95% CI 0.28–0.84

Randomised comparison

Reduced cardiovascular events

−39%−62% to −4%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.61, 95% CI 0.38–0.96

Two numbers in the abstract

the abstract, start to end

those receiving placebo (hazard ratio, 0.49; 95% confidence interval, 0.28-0.84 and hazard ratio, 0.61; 95% confidence interval,

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.490.28–0.84
Cardiovascular events
HR 0.610.38–0.96
DPP-4 inhibitorsCardiovascular events

DPP-4 inhibitors × cardiovascular eventshelps?replicated

unlikelylikely
0.990.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

9 papers cite it

2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 29581078